Clinical Trial

Combination Gerotherapeutic Interventions for Healthspan Improvement

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 16, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes. In this proof-of-concept phase, a small sample size of up to 30 subjects (10 subjects in each arm) will be randomized into one of the three arms: 1) Control, 2) Multi-therapy (B12, Naltrexone, Metformin, and NAD+), or 4) Comprehensive Therapy (Rapamycin, Naltrexone, Metformin, B12, NAD+, GSH, and Infinite Supplement).
Trial Details
NCT Number NCT07475546
Lead Sponsor AgelessRx
Conditions Healthspan Improvement, Aging, Longevity
Enrollment 30 participants
Start Date 2025-07-23
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-16